HCW Biologics Aktie

HCW Biologics für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A3CU4K / ISIN: US40423R1059

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
15.08.2025 00:33:09

Hcw Biologics Revenue Plunges 98 Percent

Hcw Biologics (NASDAQ:HCWB), a biotechnology company specializing in novel immunotherapies targeting age-related and inflammatory diseases, released its second quarter 2025 earnings on August 14, 2025. The most important news is an ongoing collapse in revenue, with only $6,550 (GAAP) recognized, missing analyst expectations of $7.0 million. However, the company sharply narrowed its net loss to $1.9 million (GAAP), primarily due to reduced legal expenses, down from a $15.3 million GAAP net loss in Q2 2024. Performance was mixed—cost controls and legal resolutions improved results, but revenue underperformance and continued balance sheet stress stand out as significant issues. Source: Analyst estimates for the quarter provided by FactSet. HCW Biologics develops immunotherapies aimed at treating diseases driven by chronic inflammation and immune dysfunction. Its core business utilizes two proprietary platforms: TOBI, which creates fusion-protein drugs, and TRBC, which engineers immunotherapies for cancer and autoimmune diseases.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Nachrichten zu HCW Biologics Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu HCW Biologics Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!